Serious Side Effects Found in New Cancer Drugs Avastin, Taxtotere, and Sutent

Comments (0)

A new study has found that new cancer drugs are associated with a significantly higher risk of side effects and more treatment-related debts than older cancer treatments. The new cancer drugs are Avastin, Taxotere, and Sutent. The potential side effects of these drugs include heart problems, skin problems, diarrhea, high blood pressure, and nerve damage. The drugs are used in the treatment of breast, colon, and lung cancer.

The researchers found that patients who were assigned to a newer drug were 40 percent more likely to die from a side effect than people who were taking a placebo. Also, patients taking the newer drugs were 52 percent more likely to have severe side effects, including nerve damage or heart problems. Those patients were also more likely to stop treatment after suffering from serious side effects. The good news is that the risk of death from cancer treatment was rare – less than one percent of the patients died from a side effect related to the treatment.

Researchers have said that the results of the study do not mean that cancer patients should not take a newer cancer drug – in some cases, the benefits of new treatment may outweigh the risk of side effects. The doctor and the patient must carefully determine how to treat cancer, and should weight the risks of treatment against the effects of the drug itself.

If you or a loved one has experienced serious, potentially deadly side effects from a cancer drug, you should talk with an attorney. Your treatment may have been the correct course of action, or you may have a legal claim against the drug manufacturer. Call the Houston personal injury attorneys at Kennedy Hodges at 855-947-0707. Call today to learn more or to schedule a free consultation. 

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."

Name:*

Email:* (will not be published)

Message:*

Notify me of follow-up comments via email.